Pseudoprogression in lung adenocarcinoma during treatment with nivolumab

BMJ Case Rep. 2017 May 12:2017:bcr2017219919. doi: 10.1136/bcr-2017-219919.

Authors

Toshihide Izumida¹, Yukio Kawagishi¹, Hiroshi Tsuji¹

Affiliation

¹ Kurobe City Hospital, Kurobe, Toyama, Japan.

No abstract available

Keywords: Lung cancer (oncology); Oncology.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / diagnostic imaging
Adenocarcinoma / drug therapy*
Adenocarcinoma of Lung
Antibodies, Monoclonal / administration & dosage*
Antineoplastic Agents / administration & dosage*
Disease Progression
Drug Administration Schedule
Fatal Outcome
Humans
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / etiology
Nivolumab
Tomography, X-Ray Computed

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Nivolumab